2020
DOI: 10.15585/mmwr.mm6925a4
|View full text |Cite
|
Sign up to set email alerts
|

Progress Toward Polio Eradication — Worldwide, January 2018–March 2020

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

2
73
0
5

Year Published

2020
2020
2022
2022

Publication Types

Select...
5
2

Relationship

1
6

Authors

Journals

citations
Cited by 71 publications
(80 citation statements)
references
References 10 publications
2
73
0
5
Order By: Relevance
“…The Global Polio Eradication Initiative has achieved its progress through extensive use of trivalent oral poliovirus vaccine (tOPV, which consists of live, attenuated Sabin vaccine strain types 1, 2, and 3). Despite the substantial advancement toward eradication attained using this vaccine, in areas with low population immunity, prolonged transmission of Sabin vaccine virus can lead to viral mutations that result in development of neurovirulent vaccine-derived polioviruses (VDPVs) (1). Outbreaks can result from VDPVs that are transmitted in a community and are known as circulating VDPVs (cVDPVs).…”
Section: Introductionmentioning
confidence: 99%
See 3 more Smart Citations
“…The Global Polio Eradication Initiative has achieved its progress through extensive use of trivalent oral poliovirus vaccine (tOPV, which consists of live, attenuated Sabin vaccine strain types 1, 2, and 3). Despite the substantial advancement toward eradication attained using this vaccine, in areas with low population immunity, prolonged transmission of Sabin vaccine virus can lead to viral mutations that result in development of neurovirulent vaccine-derived polioviruses (VDPVs) (1). Outbreaks can result from VDPVs that are transmitted in a community and are known as circulating VDPVs (cVDPVs).…”
Section: Introductionmentioning
confidence: 99%
“…PV2 disease immunity in the community was to be provided by high coverage with tOPV before the switch as well as a recommended single dose of injectable inactivated polio vaccine (IPV) to help protect against paralysis; however, suboptimal vaccination coverage and IPV manufacturing shortages have led to substantial PV2 immunity gaps in many countries (4). Since the switch, many countries, particularly in Africa, have experienced cVDPV2 outbreaks (1). To combat these outbreaks, vaccination responses with monovalent OPV2 (mOPV2) have been implemented in approximately two dozen countries.…”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations
“…(3) vaccination coverage should be high enough to achieve herd immunity at a global scale; and (4) most infections should cause symptomatic illness. Variola virus was able to meet all the four conditions, but unmet factors (3) and (4) for poliovirus and unmet factor (3) for measles virus make the ongoing effort to eradicate them challenging (Figure 2; Kew et al, 2005;Moss and Strebel, 2011;Furuse and Oshitani, 2017;Chard et al, 2020).…”
Section: Zoonotic Transmission Adaptation To Humans and Eradicationmentioning
confidence: 99%